Novobiocin synergistically increased the cytotoxic effects of the PARP inhibitors rucaparib and olaparib in BRCA1-deficient human retinal pigment epithelial cells and ovarian cancer cell lines, respectively (188). Here, BRCA1 is linked to ovarian cancer.